NZ812114A - Solid forms of pyrazolo[3,4-d]pyrimidine compounds - Google Patents
Solid forms of pyrazolo[3,4-d]pyrimidine compoundsInfo
- Publication number
- NZ812114A NZ812114A NZ812114A NZ81211422A NZ812114A NZ 812114 A NZ812114 A NZ 812114A NZ 812114 A NZ812114 A NZ 812114A NZ 81211422 A NZ81211422 A NZ 81211422A NZ 812114 A NZ812114 A NZ 812114A
- Authority
- NZ
- New Zealand
- Prior art keywords
- pyrazolo
- solid forms
- pyrimidine compounds
- solid form
- ray powder
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
The present disclosure provides solid forms of 6-((3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl)-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one, and methods of preparing and using the same.
Claims (5)
1. A solid form of Compound X: 5 wherein the solid form is selected from: Form A: characterized by having X-ray powder diffraction peaks at approximately 18.9, 20.4, and 23.1 °2? using Cu K? radiation, and Form B: characterized by having X-ray powder diffraction peaks at approximately 8.0, 15.0, and 19.3 °2? using Cu K? radiation.
2. The solid form of claim 1, wherein the solid form is Form A.
3. The solid form of claim 2, wherein the Form A is characterized by having X-ray powder ction peaks at approximately 9.6± 0.2, 17.2± 0.2, 18.9± 0.2, 20.4± 0.2, and 15 23.1± 0.2 °2? using Cu K? radiation.
4. The solid form of claim 2, wherein the Form A is characterized by having X-ray powder diffraction peaks at approximately 9.6± 0.2, 17.2± 0.2, 18.9± 0.2, 20.4± 0.2, 20.7± 0.2, 21.9± 0.2, 23.1± 0.2, and 24.5± 0.2 °2? using Cu K? radiation.
5. The solid form of claim 2, wherein the X-ray powder diffraction pattern is substantially the same to that set forth in
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163290136P | 2021-12-16 | 2021-12-16 | |
| PCT/US2022/081795 WO2023114995A1 (en) | 2021-12-16 | 2022-12-16 | Solid forms of pyrazolo[3,4-d]pyrimidine compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NZ812114A true NZ812114A (en) | 2025-08-29 |
| NZ812114B2 NZ812114B2 (en) | 2025-12-02 |
Family
ID=
Also Published As
| Publication number | Publication date |
|---|---|
| CA3242577A1 (en) | 2023-06-22 |
| US12012412B2 (en) | 2024-06-18 |
| US20240300961A1 (en) | 2024-09-12 |
| TW202333676A (en) | 2023-09-01 |
| JP2024546844A (en) | 2024-12-26 |
| IL313314A (en) | 2024-08-01 |
| CN118401525A (en) | 2024-07-26 |
| KR20240119299A (en) | 2024-08-06 |
| AU2025275149A1 (en) | 2026-01-08 |
| WO2023114995A1 (en) | 2023-06-22 |
| EP4448529A1 (en) | 2024-10-23 |
| AU2022416644B2 (en) | 2025-09-11 |
| AU2022416644A1 (en) | 2024-07-04 |
| MX2024007517A (en) | 2024-08-19 |
| US20230192707A1 (en) | 2023-06-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2024229444A3 (en) | Pyrido[4,3-d]pyrimidine derivatives as mutant kras g12c inhibitors for the treatment of cancer | |
| EP4232444A1 (en) | Heterocyclic spiro compounds and methods of use | |
| NZ590922A (en) | Piperidine derivatives as jak3 inhibitors | |
| NZ744349A (en) | Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors | |
| NZ758243A (en) | Indole ahr inhibitors and uses thereof | |
| MY146474A (en) | Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors | |
| CA2413802A1 (en) | Substituted-triazolopyrimidines as anticancer agents | |
| CA3242577A1 (en) | Solid forms of pyrazolo[3,4-d]pyrimidine compounds | |
| CA2388140A1 (en) | Alkylamino substituted bicyclic nitrogen heterocycles as inhibitors of p38 protein kinase | |
| PH12013501627A1 (en) | Compositions, suitable for oral administration, comprising a triazolo [4, 5-d]pyrimidin derivative | |
| MX2020009586A (en) | SUBSTITUTED (2-AZABICYCLO [3.1.0] HEXAN-2-YL) PYRAZOLO [1, 5-a] PYRIMIDINE AND IMIDAZO [1, 2-b] PYRIDAZINE COMPOUNDS AS TRK KINASES INHIBITORS. | |
| FI3798222T3 (en) | Crystalline form of lorlatinib free base | |
| SG10201900514RA (en) | Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors | |
| CR20240297A (en) | Salts and solid forms of an fgfr inhibitor and processes of preparing thereof | |
| NZ812114B2 (en) | Solid forms of pyrazolo[3,4-d]pyrimidine compounds | |
| ZA202401459B (en) | Monohydrate and crystalline forms of 6-[(3s,4s)-4-methyl-1- (pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl- 7h-imid azo [1,5- a] pyrazin-8-one | |
| WO2022023447A3 (en) | Fused bicyclic raf inhibitors and methods for use thereof | |
| GB2552269A (en) | Substituted pyrrolo(2,3-D)pyrimidines for selectively targeting tumor cells with fr-alpha and fr-beta type receptors | |
| FI4244208T3 (en) | A magl inhibitor | |
| CA2477516A1 (en) | Pharmaceutical formulation comprising melatonin | |
| KR960700246A (en) | 5-alkoxytriazolo (1,5-C) pyrimidine-2 (3H) -thione compound, and 2,2-dithiobistriazolo- (1,5-C) -pyrimidine) and 2-chlorosulfonyl Its use in the production of -5-alkoxytriazolo (1,5-C) pyrimidine compounds (5-Alkoxy [1,2,4] triazolo [1,5-c] pyrimidine-2 (3H) -thione compounds and their use in the preparation of 2,2'-dithiobis (5-alkoxy [1,2,4] triazolo [1,5-c] -pyrimidine) and 2-chlorosufonyl-5-alkoxy [1,2,4 ] triazolo [1,5-c] pyrimidine compounds) | |
| WO2022194909A3 (en) | Process for preparing risdiplam | |
| DE60100855D1 (en) | 1,8-NAPHTHALIMID IMIDAZO [4,5,1-DE] ACRIDONE WITH ANTITUARY EFFECT | |
| WO2025043225A3 (en) | Dioxopiperidine-indolone-methylene-carbamate compounds as degraders of cyclin-dependent kinase 2 | |
| GB9828340D0 (en) | Organic compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed |